Themistolos, secretary-general of primary health care at the Greek Ministry of Health, said on April 8 that the Greek National Vaccination Committee is considering limiting the vaccination of AstraZeneca’s new coronavirus vaccine to specific age groups and is expected to announce

Themistolos, secretary-general of primary health care at the Greek Ministry of Health, said on April 8 that the Greek National Vaccination Committee is considering limiting the vaccination of AstraZeneca’s new coronavirus vaccine to specific age groups and is expected to announce the relevant decision within two days. .

Themistolos said that despite the rare side effects of AstraZeneca's new coronavirus vaccine, the proportion of Greek people vaccinated according to the appointment time still exceeds 90%, of which 10,000 to 12,000 AstraZeneca vaccines are vaccinated every day agent.

△Pictures from the Internet

According to multiple Greek media reports, due to concerns about the safety of the AstraZeneca vaccine, more and more Greek people have canceled appointments for the vaccine. As of April 5, a total of 364,000 people in Greece had received the first dose of the AstraZeneca vaccine. Data show that the cancellation rate for appointments for the AstraZeneca vaccine is 3%, compared with about 1% for the Pfizer and Moderna COVID-19 vaccines.

The person in charge of a vaccination center in Peloponnese, Greece, said that at the beginning, about 60 doses of the new crown vaccine were administered every day, but this has now been reduced to 40 or even 30 doses.

European Medicines Agency (EMA) officials stated at a press conference held on the afternoon of April 7 that blood clots caused by the AstraZeneca vaccine are an "extremely rare" symptom and may be caused by an abnormal response of the immune system. Blood clots should be listed as a very rare side effect of the AstraZeneca vaccine.

The European Medicines Agency said it could not list specific risk factors such as age or gender, but it had found that most cases of blood clots were in women under 60. As of March 22, of the 86 cases of blood clots recorded in the European Economic Area (EU, Iceland, Norway and Liechtenstein), most of the patients were women under the age of 60, and 18 of the cases were fatal. (Reporter Wang Yuguo)

(Editor Chen Yufan)